A Phase 3 interventional study of PRC-063 and lisdexamfetamine dimesylate in Attention Deficit Hyperactivity Disorder, sponsored by Rhodes Pharmaceuticals, L.P.. Completed at 1 site in United States. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2017-01-19.
Sponsored by Rhodes Pharmaceuticals, L.P. (part of Knoa Pharma) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 181 studies testing methylphenidate in Attention Deficit Disorder with Hyperactivity — 19 open to participants now, 21 under way, 1 of them phase 3. Methylphenidate · Attention Deficit Disorder with Hyperactivity.
Among the 181 studies testing methylphenidate in Attention Deficit Disorder with Hyperactivity, this one is the 113th largest by planned enrollment of the 179 interventional ones that give a count, is one of 9 that started in 2015, is one of 43 in phase 3, and was the 127th registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →19 of the 181 studies testing methylphenidate in Attention Deficit Disorder with Hyperactivity are open now, in 7 countries. Recruiting first, the newest first:
Dar Clinical Research Inc. · Sites in Canada
Ages 65+
Hugo W. Moser Research Institute at Kennedy Krieger, Inc. · Sites in United States
Ages 6–17
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 3–5
St. Jude Children's Research Hospital · Sites in United States
Ages 8–17
NYU Langone Health · Sites in United States
Ages 18–60
By country, each count listing its studies:
Methylphenidate: first FDA approval 1955 (RITALIN), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
181 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 20 · Phase 3 47 · Phase 4 87
First in 1986; this study’s year is marked. 9 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 68 across the 179 interventional studies. Of the 138 that completed or were terminated, 55 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 181 have an industry lead sponsor. The 10 most frequent:
This study is registered under Rhodes Pharmaceuticals, L.P., one of the names counted as Knoa Pharma. Under that name alone:
Rhodes Pharmaceuticals, L.P. is the lead sponsor of 11 studies on the registry; none are open to participants now.
12 studies in Attention Deficit Disorder with Hyperactivity by Knoa Pharma: none open now, none under way, none of them phase 3. Of 11 finished, 7 (64%) have results posted.
Among the 12 studies in Attention Deficit Disorder with Hyperactivity by Knoa Pharma, this one is the 10th largest by planned enrollment, is the only one that started in 2015, is one of 7 in phase 3, and was the 8th registered.
Knoa Pharma’s Attention Deficit Disorder with Hyperactivity studies by the year they started, since 2010.
3 of the studies testing methylphenidate in Attention Deficit Disorder with Hyperactivity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05776056VA Office of Research and DevelopmentMethylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints | 2027-03-31 |
| NCT07226219St. Jude Children's Research HospitalMethylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease | 2027-07-01 |
| NCT07710014Dar Clinical Research Inc.Evaluation of Foquest in Adults 65 Years and Older With ADHD | 2027-07-21 |
Add all 3 to your calendar (.ics) → With an account.
Among the 181 studies testing methylphenidate in Attention Deficit Disorder with Hyperactivity, from their registry updates:
Among Knoa Pharma’s 12 in Attention Deficit Disorder with Hyperactivity:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this randomized, double-blind, crossover study is to compare two long-acting stimulant formulations-once-daily PRC-063 and once-daily lisdexamfetamine (LDX)-through a 15-hour period on driving performance, as measured with a driving simulator, in adult patients with ADHD.
Young adult drivers with Attention Deficit Hyperactivity Disorder (ADHD) will be compared on a driving simulator after taking PRC-063 or LDX in a repeated-measure, randomized, doubleblind, crossover study design. Each subject will be randomized to receive up to a 21-day course of PRC-063 followed by up to a 21 day course of LDX or vice versa. There will be no washout between treatments. On days 1 through 7, subjects will receive the lowest dose (45 mg of PRC-063 or 30 mg of LDX) of study medication. On days 8 through 14, subjects will receive the middle dose (70 mg of PRC-063 or 50 mg of LDX). On days 15 through 21, subjects will receive the highest dose (100 mg of PRC-063 or 70 mg of LDX). During Days 1 through 21, if a subject is responding satisfactorily to medication, he or she may remain on that daily dose. Driving laboratory testing will be conducted between Day 17 and Day 21. Following the laboratory testing, the subject will begin a second titration of the alternate treatment, starting on Day 22 through Day 28 at the lowest dose (45 mg of PRC-063 or 30 mg of LDX) of study medication, Day 29 through Day 35 on the middle dose (70 mg of PRC-063 or 50 mg of LDX) and Day 36 through Day 42 on the highest dose (100 mg of PRC-063 or 70 mg of LDX). During Days 22 through 42, if a subject is responding satisfactorily to medication, he or she may remain on that daily dose. Following titration with the second treatment, subjects will attend a second driving laboratory testing, conducted between Day 38 to Day 42. Subjects will subsequently attend a safety and study termination visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or non-pregnant, non-nursing female at least 18 years of age and less than or equal to 25 years of age with a valid driver's license and at least six months of driving experience with driving activity at least twice per week.
ADHD diagnosis, inattentive, hyperactive/impulsive or combined, as defined by the , 5th Edition (DSM-5) based on clinician assessment using the Structured Clinical Interview for DSM Disorders (SCID).
Dissatisfaction with his or her current pharmacological therapy for treatment of ADHD or not currently receiving pharmacological therapy for ADHD. Inclusion of subjects naïve to pharmacological therapy for ADHD is permitted.
Exclusion Criteria:
Known to be non-responsive to methylphenidate or lisdexamfetamine treatment. Nonresponse is defined as methylphenidate or lisdexamfetamine use at various doses for a phase of at least four weeks at each dose with little or no clinical benefit in the last 10 years.
Having a history of motion, sea or big screen (e.g. IMAX) sickness, in order to avoid possible Simulation Adaptation Syndrome.
Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Titration during which subjects will be titrated from a starting dose of 45 mg/day (dosed once daily) of PRC-063 oral capsules up to his/her final dose (45, 70 or 100 mg/day of PRC-063). This phase will be 10 to 21 days long.
Drug: PRC-063 · Drug: Placebo
Titration during which subjects will be titrated from a starting dose of 30 mg/day of lisdexamfetamine up to his/her final dose (30, 50 or 70 mg/day of LDX). This phase will be 10 to 21 days long.
Drug: lisdexamfetamine dimesylate · Drug: Placebo
Subjects will be dosed once daily with a placebo oral capsule for 10 to 21 days.
Drug: Placebo
Oral extended-release capsule
Oral capsule
Oral placebo capsule
Tactical Driving Quotient (TDQ)
The primary outcome measure will be the Tactical Driving Quotient (TDQ) between treatments. The TDQ is an accumulative effect size across multiple driving variables collected during the driving simulation, including: summed standard deviations of steering, driving off the road, veering across the midline, inappropriate braking while on the open road, missed stop signs, exceeding speed limit, standard deviation of speed, time at stop sign deciding when to turn left and time to complete left turns. A higher TDQ score reflects better driving skill. A TDQ of 100 represents average driving and the standard deviation of normal distribution is 15. The normal range of driving (+/- 1.0 SD) is 85 to 115. A TDQ of less than 100 represents worse than average driving (e.g., a TDQ of 115 represents driving performance 1 SD better than average) and a TDQ of greater than 100 represents better than average driving.
Time frame: At 21 days (Visit 9)
Number of Participants with Adverse Events
Summary of adverse events reported during the study
Time frame: Participants will be followed for the duration of the study, an expected average of 10 weeks
Columbia Suicide Severity Rating Scale (CSSRS)
A Columbia Suicide Severity Rating Scale (CSSRS) assessment will be administered by the investigator to all study participants
Time frame: At one week and nine weeks of the study
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Sep 2015, a primary completion of Jan 2017 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Methylphenidate · Lisdexamfetamine
Attention Deficit Disorder with Hyperactivity →
Rhodes Pharmaceuticals, L.P. →